Citigroup
AYTU icon

Citigroup’s AYTU BioPharma AYTU Stock Holding History

Citigroup’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$3 – 5950
2025
Q4 		$3 Hold
1
– – ﹤0.01% 5897
2025
Q3 		$2 Buy
+1
New +$2 ﹤0.01% 6017
2024
Q1 		– Sell
-1
Closed -$3 – 5634
2023
Q4 		$3 Buy
+1
New +$3 ﹤0.01% 5655
2023
Q1 		– Sell
-2,618
Closed -$9.9K – 5492
2022
Q4 		$9.9K Buy
+2,618
New +$9.86K ﹤0.01% 4843
2022
Q3 		– Hold
0
– – – 5825
2022
Q2 		– Hold
0
– – – 6231
2022
Q1 		– Hold
0
– – – 6300
2021
Q4 		– Hold
0
– – – 5818
2021
Q3 		– Sell
-40
Closed -$3K – 5755
2021
Q2 		$4K Sell
40
-76
-66% -$8.92K ﹤0.01% 5867
2021
Q1 		$18K Buy
116
+93
+404% +$14.8K ﹤0.01% 5300
2020
Q4 		$3K Buy
23
+17
+283% +$3.1K ﹤0.01% 7183
2020
Q3 		$1K Sell
6
-9
-60% -$2.31K ﹤0.01% 7351
2020
Q2 		$4K Buy
+15
New +$4.54K ﹤0.01% 7302
2020
Q1 		– Hold
0
– – – 7589
2018
Q1 		– Hold
0
– – – 7528
2017
Q4 		– Hold
0
– – – 7546

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's AYTU Position: Q1 2026 in Review

Citigroup sold out of AYTU BioPharma (AYTU) in Q1 2026, closing a stake of 1 share — an estimated $3 sold.

Citigroup first reported a position in AYTU in Q2 2020 and held it in 9 quarters. The position peaked at $18K in Q1 2021. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Citigroup reported no remaining AYTU BioPharma position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 AYTU BioPharma share in Q1 2026, an estimated $3.
  • Citigroup first reported a position in AYTU BioPharma in Q2 2020 and held it in 9 quarters.
  • Citigroup's AYTU BioPharma position peaked at $18K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.